COMMUNIQUÉS West-GlobeNewswire

Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy
16/10/2026
Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, [...]
twiist™ Automated Insulin Delivery System is Now Cleared for Adults with Type 2 Diabetes
16/10/2026
Clearance expands twiist's precise insulin delivery and personalized automation to the largest population of people treated with insulin, with time-in-range improvements seen in as little as one day in a pivotal trial 1 [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16/10/2026
PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director
16/10/2026
OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director Oxford, UK – 16 October 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Dr [...]
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
16/10/2026
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed [...]
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
16/10/2026
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a [...]
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
16/10/2026
REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham 32% of Revita ® participants in [...]
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
16/10/2026
Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization Will lead AT177 through IND-enabling [...]
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
16/10/2026
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Semax Peptide Introduced by Kylo Peptides for Laboratory Use
16/10/2026
Sheridan, Wyoming, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has added Semax [ https://kylopeptides.com/product/semax/ ] to its research catalog this week. The compound is a synthetic peptide supplied only for [...]
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma
16/10/2026
If approved, TALVEY ® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second line CHMP recommendation based on Phase 3 [...]
Senturi Pharma announces exclusive European distribution agreement for PERTZYE®
16/10/2026
STOCKHOLM, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Senturi Pharma AB and Digestive Care, Inc. today announced the signing of an exclusive distribution agreement concerning PERTZYE ® (pancrelipase) in Europe. Under the [...]
Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology
16/10/2026
BEIJING, Oct. 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies [...]
IBA and Framatome join forces to industrialize Astatine-211 production for cancer therapies
16/10/2026
Louvain-la-Neuve, Belgium, and Paris, France, 16 October 2026, 8:00 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, [...]
IBA et Framatome s’associent pour industrialiser la production d’Astate-211 au service des thérapies contre le cancer
16/10/2026
Louvain-la-Neuve, Belgique, et Paris, France, le 16 octobre 2026, 8h00 – IBA (Ion Beam Applications, EURONEXT), leader mondial des technologies d'accélérateurs de particules et des solutions de production en médecine [...]
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
16/10/2026
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, [...]
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
16/10/2026
Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer NANJING, China , Oct. 16, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887. [...]
City Therapeutics Announces Pricing of Upsized Initial Public Offering
16/10/2026
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi [...]
Paretofit Announces Founder Tobias Burkhardt's Feature in Prime Today on Sustainable Performance for Entrepreneurs
15/10/2026
The cover story explores how the German health sociologist applies evidence-based 80/20 principles to help self-employed professionals and entrepreneurs build sustainable personal health systems. Cologne, Germany, Oct. [...]

Pages